Conference Coverage

Bladder Toxicity After Volumetric Arc Radiation Therapy (VMAT) Treatment for Prostate Cancer Following Prostatectomy

Abstract: 2018 AVAHO Meeting


 

Methods: We did a retrospective review of 55 patients with prostate cancer treated using external beam radiation therapy VMAT between 2013 through 2017.

Results: Sixteen were adjuvant/salvage therapy to the prostate fossa (PF) after a prostatectomy while 39 had primary radiation therapy for intact prostate cancer. The dose volume histogram (DVH) institutional bladder constraints were v65 200 cc, 55% when > 150 cc and there were no incidences of hematuria when the PTV was < 150 cc.

Conclusions: (1) Overall incidence of hematuria with VMAT treatment to the prostate was 10/55(18%); (2) Higher bladder DVH v65 volumes correlated with higher incidence of hematuria; (3) Higher PTV in PF group correlated with higher incidence of hematuria with the greatest risk occurring when the PTV was greater than 200 cc. This is due to more bladder in the treatment field; (4) Careful patient selection should be made for surgery to avoid post-surgery radiation therapy; (5) When treating PF keep the PTV volume under 150 cc; and (6) This finding should be studied with larger number of patients.

Recommended Reading

Treatment and Management of Patients With Prostate Cancer (FULL)
AVAHO
Secondary Cancers After Prostate Cancer: What’s the Risk?
AVAHO
Innovations Lead to More Targeted Prostate Cancer Treatments (FULL)
AVAHO
Occurrence of Skeletal-Related Events in Multiple Myeloma and Prostate Cancer Patients Receiving Standard Versus Extended-Interval Zoledronic Acid
AVAHO
Improving Prostate Cancer Education Among Veterans at the Palo Alto VA
AVAHO
Implementation of Dietary Education Within a Multidisciplinary Team Approach to Improve Treatment Accuracy and Efficiency in Prostate Cancer External Beam Radiation Therapy
AVAHO
Efficacy of Enzalutamide and Abiraterone Sequences in Metastatic Castration-Resistant Prostate Cancer
AVAHO
Association of Prostate-Specific Antigen (PSA) Trajectories With Mortality in Veterans With Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
AVAHO
Survival Rates of Black and White Veterans With Metastatic Castration-Resistant Prostate Cancer
AVAHO
Presentation of A Rare Malignancy: Leiomyosarcoma of the Prostate
AVAHO